A substantial advancement in glucose treatment is emerging with the introduction of tirzepatide at a dosage of 45mg. This updated offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 target, https://bookmarkfavors.com/story7006459/revolutionary-development-tirzepatide-45mg-for-diabetes-management